Latest News and Press Releases

Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) ...

Dublin, May 01, 2025 (GLOBE NEWSWIRE) -- The "Advanced Drug Delivery Systems - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The Global Advanced Drug Delivery...

Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) --...

Dublin, April 22, 2025 (GLOBE NEWSWIRE) -- The "Long-Acting Drug Delivery Technologies and Services Market: Focus on Technology, Dosage Form, Type of Molecule Delivered, Material, Distribution...

Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- The "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic...

Dublin, April 10, 2025 (GLOBE NEWSWIRE) -- The "Smart Drug Delivery Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...

Dublin, April 09, 2025 (GLOBE NEWSWIRE) -- The "Nanorobots for Drug Delivery Market by Type (Endogenous Power Driven, Exogenous Power Driven), Procedure Type (Chemotherapy, Radiotherapy),...

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market...

KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for...